Related Experiment Videos
Prostaglandins and metastasis.
Symposium on Fundamental Cancer Research
|January 1, 1983
Summary
Prostaglandin D2 and interferons reduce cancer metastasis by affecting platelet aggregation and macrophage activity. These findings highlight natural modulators of host resistance in controlling tumor spread.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Metastasis is a complex process involving tumor cell evasion of host defenses and interaction with platelets.
- Prostaglandins and interferons are known modulators of cellular functions and immune responses.
Purpose of the Study:
- To investigate the role of prostaglandin D2 (PGD2) and interferons in modulating tumor metastasis.
- To explore the mechanisms by which these mediators affect cancer cell spread, including platelet aggregation and macrophage cytotoxicity.
Main Methods:
- In vitro experiments using F1 and F10 melanoma cells and C57 black mouse platelets.
- Assessment of platelet aggregation, macrophage cytotoxicity against B16 target cells, and lung metastasis rates.
- Interferon treatment to stimulate PGD2 synthesis and evaluate its effect on metastasis.
Main Results:
- An inverse relationship was observed between metastasis levels and PGD2 production in F1 and F10 cells.
- PGD2 and prostacyclin reduced platelet aggregation in vitro.
- PGD2 decreased macrophage cytotoxicity against B16 cells.
- Interferons stimulated PGD2 synthesis in F10 cells and reduced lung metastasis, with broader in vivo activity than solely PGD2 induction.
Conclusions:
- Prostaglandins and interferons significantly impact tumor cell metastasis.
- Mechanisms include modulation of platelet aggregation and host immune defenses like macrophages.
- The B16 melanoma model offers a system to study the role of PGD2 and related mediators in metastasis.